Intravitreal administration of recombinant human opticin protects against hyperoxia-induced pre-retinal neovascularization. (2022)
Attributed to:
Development of an opticin-based anti-angiogenic therapeutic for the treatment of ocular disease.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.exer.2021.108908
PubMed Identifier: 34954204
Publication URI: http://europepmc.org/abstract/MED/34954204
Type: Journal Article/Review
Volume: 215
Parent Publication: Experimental eye research
ISSN: 0014-4835